The present invention relates to a pharmaceutical combination composition comprising at least one HMG-CoA reductase inhibitor in a subtherapeutic dose and which is designed to prevent and/or to reduce the ageing of the body, particularly for use in prevention, reduction or reversal of arterial ageing in apparently healthy subjects.
